ArcherDX, Illumina Launch Collaboration
News May 31, 2016
ArcherDX, Inc. has announced an agreement to develop next-generation sequencing (NGS) based in vitro diagnostic (IVD) tests with Illumina, Inc. Under terms of the agreement, ArcherDX will lead the development of a series of diagnostic tests utilizing Archer's Anchored Multiplex PCR (AMP™) chemistry that will be run on the Illumina MiSeqDx® instrument. This agreement reflects the commitment of both companies to provide NGS-based diagnostics to support current and future clinical trials.
"The ArcherDX-Illumina partnership enables our vision of creating a companion test aligned to the current and next generations of targeted therapies, rather than a single companion diagnostic targeting a single targeted therapy. This will dramatically improve patient outcomes and lower the sample and cost burdens of clinical sequencing in the future."
"This approach is a paradigm shift from the ‘one test for one drug’ method. In recent years, we have seen targeted drugs against ALK and ROS1 translocations approved in record time, and targets like NTRK, MET and FGFR are not far behind. By partnering with multiple pharmaceutical companies and Illumina in a shared mission against cancer, ArcherDX now has all the pieces required to take an end-to-end NGS diagnostic assay through a regulated process."
- Jason Myers, Ph.D., CEO at ArcherDX
“Illumina is committed to enabling the development of companion diagnostics using NGS,” said John Leite Ph.D., Vice President of Market Development for Oncology at Illumina. “We are pleased to partner with ArcherDX to expand IVD test offerings on the MiSeqDx instrument.”
“The proven sequencing quality from the MiSeqDx system, when paired with ArcherDX's ability to interrogate small amounts of RNA and DNA from FFPE samples, has already enabled the detection of novel, actionable alterations from clinical sample types,” said Stephen Picone, Executive Director of Corporate Development at ArcherDX. “A companion diagnostic assay that combines Archer technology with Illumina instrumentation is a major step towards fulfilling what we set out to do.”
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
Nano-tech Diagnostic Can Indicate Cancer or Thrombotic Risk in One Drop of BloodNews
A team of international researchers led by Professor Martin Hegner, Investigator in CRANN and Trinity’s School of Physics, have developed an automated diagnostic platform that can quantify bleeding – and thrombotic risks – in a single drop of blood, within seconds.READ MORE
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE